Sensyne Health signs Strategic Research Agreement with South Warwickshire NHS Foundation Trust

Sensyne Health signs Strategic Research Agreement with South Warwickshire NHS Foundation Trust

July 31, 2018

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

New research collaboration aims to analyse anonymised patient data across community and acute care using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.

Oxford, UK; 31st July 2018: Sensyne Health (the “Company”), formerly named Drayson Health, a British clinical AI technology company, announces today that it has signed a Strategic Research Agreement (SRA) with South Warwickshire NHS Foundation Trust (SWFT), to analyse the Trust’s anonymised patient data using Sensyne Health’s clinical artificial intelligence (Clinical AI) technology. This news follows an announcement made by the Company and the Trust on 5 July that a Memorandum of Understanding (MOU) had been signed.

South Warwickshire NHS Foundation Trust (SWFT) is an integrated organisation that provides acute and community NHS health services to half a million people across Warwickshire, in addition to specialist services in Coventry and Solihull. The composition of the organisation means it provides healthcare services across community, out-patient and acute care facilities, and so generates a valuable source of patient information that can be anonymised and contribute to medical research and the development of new treatments.

This new agreement enables Sensyne Health to analyse anonymised patient data provided by SWFT using the Company’s Clinical AI platform. The agreement also includes a new research collaboration between the parties in digital health and biomedical research. SWFT now joins Oxford University Hospitals NHS Foundation Trust and the University of Oxford which signed a similar agreement with Sensyne Health in July 2017.  The purpose of the research collaboration is to derive new insights that will improve the care of the Trust’s patients and help to find new treatments.  

Research will be undertaken to the highest standards of information governance and data security in accordance with the Caldicott Principles and data protection legislation.

GLEN BURLEY, CEO, SOUTH WARWICKSHIRE NHS FOUNDATION TRUST, COMMENTED:
“We are excited to continue working with Sensyne Health. The ability to use clinical artificial intelligence will support research advancements, helping to make improvements in clinical efficiency and safety.”
LORD (PAUL) DRAYSON, CEO OF SENSYNE HEALTH, COMMENTED:
“We are delighted to be working with South Warwickshire NHS Foundation Trust to bring the benefits of the latest clinical AI research to improve care for their patients and develop new treatments together.”

For more information please contact:

Sensyne Health
Laura Steward
T: +44 (0) 330 058 1845 | M: +44 (0)7899 061975
E: laura.steward@sensynehealth.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
T: +44 20 3709 5700
E: sensynehealth@consilium-comms.com
www.consilium-comms.com

Notes for editors:
ABOUT SENSYNE HEALTH

Sensyne Health is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with the Caldicott Principles, UK data protection law and applicable regulatory guidance.

Sensyne Health, which recently changed its name from Drayson Health, is based in the Big Data Institute at the University of Oxford's Old Road Campus.

For more information, please visit: www.sensynehealth.com

ABOUT SOUTH WARWICKSHIRE NHS FOUNDATION TRUST

South Warwickshire NHS Foundation Trust (SWFT) provides the hospital services to South Warwickshire from four hospitals:

  • Warwick Hospital
  • Leamington Spa Hospital
  • Stratford Hospital
  • Ellen Badger Hospital

We also deliver out-of-hospital community services to the whole of Warwickshire serving a population of more than half a million from various clinics.

WHAT IS ‘CLINICAL AI’?

Clinical AI is a highly specialised field of AI which uses machine learning algorithms, including deep learning in tandem with human clinical expertise and big datasets with which to train the algorithms. Clinical AI is particularly concerned with the analysis of data acquired during routine clinical care of patients, in order to derive clinically-useful results such as to improve patient outcomes and to discover new insights about the use of pharmaceutical compounds to treat patients.

DISCLAIMER

This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.

These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.

Oxford Office

Schrödinger Building,
Heatley Road, Oxford Science Park,
Oxford, OX4 4GE

Schrödinger Building,
Heatley Road, Oxford Science Park,
Oxford, OX4 4GE

+44 (0) 330 058 1845

Contact us

For press enquiries, please contact press@sensynehealth.com